文献速递神经肿瘤

神经肿瘤临床试验的资助来源、利益冲突与阳性结论

Funding source, conflict of interest and positive conclusions in neuro-oncology clinical trials.
PubMed 文献 · J Neurooncol · 2017-11-21

该综述检索2010年2月至2015年2月发表的中枢神经系统恶性肿瘤临床试验,由两名研究者独立将结论按作者对实验性治疗的认可程度分类,用统计模型检验阳性结论与试验特征的关系。结果发现资助来源和自报利益冲突似乎不影响结论,但资金来源和利益冲突披露不足。

要点

  • 仅行业资助、仅学术机构资助、学术与行业共同资助、无资助、未描述资助来源的试验中阳性结论比例分别为56.8%、55.6%、44.1%、77.8%、76.4%(p=0.011)。
  • 与无关利益冲突、相关利益冲突、未报告利益冲突的试验中阳性结论比例分别为60.4%、60%、60%(p=0.997)。
  • I期试验、北美或欧洲以外地区、非总生存或进展生存为主要终点、未披露资助来源与阳性结论显著相关。

核心结论

  • 资助来源和自报利益冲突似乎不影响中枢神经系统试验的结论。
  • 需要持续努力以提高利益冲突和资助来源的报告率。

研究设计与样本

  • 对过去5年发表的中枢神经系统恶性肿瘤临床试验进行综述。
  • 两名研究者独立根据作者对实验性治疗的认可程度对研究结论进行分类。
  • 从2010年2月至2015年2月共检索到1256篇文章,其中319篇被视为合格试验。

主要发现

  • 仅行业资助的试验阳性结论比例为56.8%,仅学术机构资助为55.6%,学术与行业共同资助为44.1%,无资助为77.8%,未描述资助来源为76.4%(p=0.011)。
  • 与无关利益冲突的试验阳性结论比例为60.4%,与相关利益冲突为60%,未报告利益冲突为60%(p=0.997)。
  • 与阳性结论显著相关的因素包括:I期试验[OR 11.64(95 CI 4.66-29.09),p < 0.001]、北美或欧洲以外地区[OR 1.96(95 CI 1.05-3.79),P = 0.025]、非总生存或进展生存为主要终点[OR 3.74(95 CI 2.27-6.18),p < 0.001]、未披露资助来源[OR 2.45(95 CI 1.22-5.22),p = 0.011]。
  • 在多变量回归模型中,所有这些因素仍与试验的阳性结论显著相关。
  • 资助来源信息和利益冲突披露在中枢神经系统试验中分别有14.1%和17.2%报告不足。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We aimed to test any association between authors' conclusions and self-reported COI or funding sources in central nervous system (CNS) studies. A review was performed for CNS malignancy clinical trials published in the last 5 years. Two investigators independently classified study conclusions according to authors' endorsement of the experimental therapy. Statistical models were used to test for associations between positive conclusions and trials characteristics. From February 2010 to February 2015, 1256 articles were retrieved; 319 were considered eligible trials. Positive conclusions were reported in 56.8% of trials with industry-only, 55.6% with academia-only, 44.1% with academia and industry, 77.8% with none, and 76.4% with not described funding source (p = 0.011). Positive conclusions were reported in 60.4% of trials with unrelated COI, 60% with related COI, and 60% with no COI reported (p = 0.997). Factors that were significantly associated with the presence of positive conclusion included trials design (phase 1) [OR 11.64 (95 CI 4.66-29.09), p < 0.001], geographic location (outside North America or Europe) [OR 1.96 (95 CI 1.05-3.79), P = 0.025], primary outcomes (non-overall or progression free survival) [OR 3.74 (95 CI 2.27-6.18), p < 0.001], and failure to disclose funding source [OR 2.45 (95 CI 1.22-5.22), p = 0.011]. In a multivariable regression model, all these factors remained significantly associated with trial's positive conclusion. Funding source and self-reported COI did not appear to influence the CNS trials conclusion. Funding source information and COI disclosure were under-reported in 14.1 and 17.2% of the CNS trials. Continued efforts are needed to increase rates of both COI and funding source reporting.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Moraes FY, Mendez LC, Taunk NK, et al. Funding source, conflict of interest and positive conclusions in neuro-oncology clinical trials. J Neurooncol. 2017. PMID: 29164521. doi:10.1007/s11060-017-2687-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。